Lexicon Pharma (LXRX) Tops Q4 EPS by 14c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Needham & Company Downgrades Lexicon Pharmaceuticals (LXRX) to Hold
February 23, 2018 7:14 AM ESTNeedham & Company downgraded Lexicon Pharmaceuticals (NASDAQ: LXRX) from Buy to Hold.
Analsyt Alan Carr commented, "Lexicon reported $5.4M U.S. Xermelo 4Q17 sales (+3% q/q), below our and consensus $7.5M ests. Challenges include low number of patient starts and a large number... More
Lexicon Pharmaceuticals (LXRX) PT Lowered to $25 at Stifel; 'Despite Slow Xermelo Progress, We Still Can’t Reconcile Valuation Here'
February 22, 2018 5:20 PM ESTStifel lowered its price target on Lexicon Pharmaceuticals (NASDAQ: LXRX) to $25.00 (from $27.00) while maintaining a Buy rating.
... More